Clinical Trials for Non-Small Cell Lung Cancer

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with selected histiocytic neoplasms, higher-risk MDS, CMML, primary myelofibrosis, or specified lymphomas or CLL/SLL who generally have relapsed or refractory disease or limited standard treatment options receive oral Q702 (adrixetinib) alone. Q702 is an investigational AXL, MER, and CSF1R inhibitor given intermittently in 28-day cycles.

ClinicalTrials.gov ID: NCT06712810

A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and selected advanced or metastatic solid tumors receive AZD6750, an investigational CD8-guided IL-2 agent designed to preferentially stimulate CD8-positive T cells. A separate cohort of patients with stage IV NSCLC receives AZD6750 plus rilvegostomig, an investigational PD-1/TIGIT bispecific antibody.

ClinicalTrials.gov ID: NCT07115043

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors that have progressed after at least one systemic therapy receive FT836, an off-the-shelf, induced pluripotent stem cell–derived CAR T-cell therapy targeting MICA/MICB. FT836 is given alone or with paclitaxel, cetuximab, or trastuzumab, including paclitaxel–antibody combinations.

ClinicalTrials.gov ID: NCT07216105

A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or recurrent NSCLC and ECOG 0–1 are eligible for cohorts spanning previously treated disease, including EGFR-mutant disease after EGFR inhibitors, and untreated disease without actionable alterations. Treatment centers on BNT326, a HER3-directed antibody–drug conjugate delivering a topoisomerase-I inhibitor, plus BNT327, a PD-L1/VEGF-A bispecific antibody; selected cohorts also evaluate either drug alone or compare the combination with first-line pembrolizumab-based treatment.

ClinicalTrials.gov ID: NCT07111520

A Phase 1b, Two-Part Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic NSCLC and ECOG 0–1 receive intratumoral tolododekin alfa (ANK-101), a tumor-retained IL-12 formulation intended to stimulate T-cell and natural killer cell activity. Patients whose disease progressed after PD-1/PD-L1 blockade and platinum chemotherapy also receive investigational anti-PD-1 antibody cetrelimab; those untreated for advanced disease receive an investigator-selected approved anti-PD-1/PD-L1 antibody.

ClinicalTrials.gov ID: NCT07027514

A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, measurable metastatic or locally advanced head and neck, lung, gastrointestinal, pancreatic, cervical, endometrial, or urothelial cancer receive STRO-004 alone or with pembrolizumab. STRO-004 is a tissue factor–targeted antibody–drug conjugate that delivers the topoisomerase I inhibitor exatecan.

ClinicalTrials.gov ID: NCT07227168

A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-711 as a Monotherapy or in Combination With Budigalimab (ABBV-181) in Adult Subjects With Advanced Squamous Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced squamous tumors who have progressed after standard therapy or cannot receive it are eligible; expansion cohorts focus on squamous non-small cell lung cancer and head and neck squamous cell carcinoma. Treatment is oral ABBV-711, an investigational PARP7 inhibitor, alone or with intravenous budigalimab, an anti-PD-1 antibody.

ClinicalTrials.gov ID: NCT07241039

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with metastatic KRAS G12C-mutant NSCLC who have progressed after or cannot tolerate platinum chemotherapy and PD-L1–targeted immunotherapy receive amivantamab, an EGFR/MET bispecific antibody, plus olomorasib, an investigational KRAS G12C inhibitor. Prior KRAS inhibitor treatment is excluded.

ClinicalTrials.gov ID: NCT07227025

A Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with advanced or recurrent NFE2L2- or KEAP1-altered NSCLC that has progressed after chemotherapy and immune checkpoint inhibition receive subcutaneous DRP-104 twice weekly. DRP-104 is a tumor-targeted prodrug of DON, a glutamine antagonist that inhibits multiple glutamine-utilizing enzymes.

ClinicalTrials.gov ID: NCT07249372

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, measurable MTAP-deleted advanced solid tumors (ECOG 0–1) receive oral IDE892 alone or with IDE397; dose-expansion cohorts are limited to NSCLC. IDE892 is an MTA-cooperative PRMT5 inhibitor, and IDE397 is a MAT2A inhibitor.

ClinicalTrials.gov ID: NCT07277413